These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17219151)

  • 1. An MVA vaccine overcomes tolerance to human p53 in mice and humans.
    Song GY; Gibson G; Haq W; Huang EC; Srivasta T; Hollstein M; Daftarian P; Wang Z; Diamond D; Ellenhorn JD
    Cancer Immunol Immunother; 2007 Aug; 56(8):1193-205. PubMed ID: 17219151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model.
    Ishizaki H; Manuel ER; Song GY; Srivastava T; Sun S; Diamond DJ; Ellenhorn JD
    Cancer Immunol Immunother; 2011 Jan; 60(1):99-109. PubMed ID: 20960189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model.
    Espenschied J; Lamont J; Longmate J; Pendas S; Wang Z; Diamond DJ; Ellenhorn JD
    J Immunol; 2003 Mar; 170(6):3401-7. PubMed ID: 12626601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterologous prime/boost immunization with p53-based vaccines combined with toll-like receptor stimulation enhances tumor regression.
    Ishizaki H; Song GY; Srivastava T; Carroll KD; Shahabi V; Manuel ER; Diamond DJ; Ellenhorn JD
    J Immunother; 2010; 33(6):609-17. PubMed ID: 20551836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.
    Daftarian P; Song GY; Ali S; Faynsod M; Longmate J; Diamond DJ; Ellenhorn JD
    Cancer Res; 2004 Aug; 64(15):5407-14. PubMed ID: 15289349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant modified vaccinia virus ankara (MVA) expressing wild-type human p53 induces specific antitumor CTL expansion.
    Song GY; Srivastava T; Ishizaki H; Lacey SF; Diamond DJ; Ellenhorn JD
    Cancer Invest; 2011 Oct; 29(8):501-10. PubMed ID: 21843052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma.
    Pulaski BA; Clements VK; Pipeling MR; Ostrand-Rosenberg S
    Cancer Immunol Immunother; 2000 Apr; 49(1):34-45. PubMed ID: 10782864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV model.
    Ishida E; Lee J; Campbell JS; Chakravarty PD; Katori Y; Ogawa T; Johnson L; Mukhopadhyay A; Faquin WC; Lin DT; Wirth LJ; Pierce RH; Pai SI
    Cancer Immunol Immunother; 2019 Aug; 68(8):1273-1286. PubMed ID: 31243491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alteration of the Tumor Stroma Using a Consensus DNA Vaccine Targeting Fibroblast Activation Protein (FAP) Synergizes with Antitumor Vaccine Therapy in Mice.
    Duperret EK; Trautz A; Ammons D; Perales-Puchalt A; Wise MC; Yan J; Reed C; Weiner DB
    Clin Cancer Res; 2018 Mar; 24(5):1190-1201. PubMed ID: 29269377
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase I dendritic cell p53 peptide vaccine for head and neck cancer.
    Schuler PJ; Harasymczuk M; Visus C; Deleo A; Trivedi S; Lei Y; Argiris A; Gooding W; Butterfield LH; Whiteside TL; Ferris RL
    Clin Cancer Res; 2014 May; 20(9):2433-44. PubMed ID: 24583792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Xenogeneic human p53 DNA vaccination by electroporation breaks immune tolerance to control murine tumors expressing mouse p53.
    Soong RS; Trieu J; Lee SY; He L; Tsai YC; Wu TC; Hung CF
    PLoS One; 2013; 8(2):e56912. PubMed ID: 23457640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines.
    Arlen P; Tsang KY; Marshall JL; Chen A; Steinberg SM; Poole D; Hand PH; Schlom J; Hamilton JM
    Cancer Immunol Immunother; 2000 Dec; 49(10):517-29. PubMed ID: 11129322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
    Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
    Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response.
    Zhao L; Mei Y; Sun Q; Guo L; Wu Y; Yu X; Hu B; Liu X; Liu H
    J Immunol; 2014 Jul; 193(2):735-45. PubMed ID: 24943214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An experimental vaccine expressing wild-type p53 induces protective immunity against glioblastoma cells with high levels of endogenous p53.
    Blaszczyk-Thurin M; Ertl IO; Ertl HC
    Scand J Immunol; 2002 Oct; 56(4):361-75. PubMed ID: 12234257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model.
    Eralp Y; Wang X; Wang JP; Maughan MF; Polo JM; Lachman LB
    Breast Cancer Res; 2004; 6(4):R275-83. PubMed ID: 15217493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer.
    NoeDominguez-Romero A; Zamora-Alvarado R; Servín-Blanco R; Pérez-Hernández EG; Castrillon-Rivera LE; Munguia ME; Acero G; Govezensky T; Gevorkian G; Manoutcharian K
    Hum Vaccin Immunother; 2014; 10(11):3201-13. PubMed ID: 25483665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward the development of multi-epitope p53 cancer vaccines: an in vitro assessment of CD8(+) T cell responses to HLA class I-restricted wild-type sequence p53 peptides.
    Sakakura K; Chikamatsu K; Furuya N; Appella E; Whiteside TL; Deleo AB
    Clin Immunol; 2007 Oct; 125(1):43-51. PubMed ID: 17631051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.